258 related articles for article (PubMed ID: 19549919)
1. Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4.
Xie Y; Wolff DW; Wei T; Wang B; Deng C; Kirui JK; Jiang H; Qin J; Abel PW; Tu Y
Cancer Res; 2009 Jul; 69(14):5743-51. PubMed ID: 19549919
[TBL] [Abstract][Full Text] [Related]
2. Pristimerin inhibits breast cancer cell migration by up- regulating regulator of G protein signaling 4 expression.
Mu XM; Shi W; Sun LX; Li H; Wang YR; Jiang ZZ; Zhang LY
Asian Pac J Cancer Prev; 2012; 13(4):1097-104. PubMed ID: 22799288
[TBL] [Abstract][Full Text] [Related]
3. RGS3 and RGS4 differentially associate with G protein-coupled receptor-Kir3 channel signaling complexes revealing two modes of RGS modulation. Precoupling and collision coupling.
Jaén C; Doupnik CA
J Biol Chem; 2006 Nov; 281(45):34549-60. PubMed ID: 16973624
[TBL] [Abstract][Full Text] [Related]
4. Concerted stimulation and deactivation of pertussis toxin-sensitive G proteins by chimeric G protein-coupled receptor-regulator of G protein signaling 4 fusion proteins: analysis of the contribution of palmitoylated cysteine residues to the GAP activity of RGS4.
Bahia DS; Sartania N; Ward RJ; Cavalli A; Jones TL; Druey KM; Milligan G
J Neurochem; 2003 Jun; 85(5):1289-98. PubMed ID: 12753087
[TBL] [Abstract][Full Text] [Related]
5. Palmitoylation of a conserved cysteine in the regulator of G protein signaling (RGS) domain modulates the GTPase-activating activity of RGS4 and RGS10.
Tu Y; Popov S; Slaughter C; Ross EM
J Biol Chem; 1999 Dec; 274(53):38260-7. PubMed ID: 10608901
[TBL] [Abstract][Full Text] [Related]
6. DHHC protein-dependent palmitoylation protects regulator of G-protein signaling 4 from proteasome degradation.
Wang J; Xie Y; Wolff DW; Abel PW; Tu Y
FEBS Lett; 2010 Nov; 584(22):4570-4. PubMed ID: 21035448
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.
Kang JH; Song KH; Jeong KC; Kim S; Choi C; Lee CH; Oh SH
BMC Cancer; 2011 Aug; 11():334. PubMed ID: 21813027
[TBL] [Abstract][Full Text] [Related]
8. c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2.
Li X; Liu X; Xu W; Zhou P; Gao P; Jiang S; Lobie PE; Zhu T
J Biol Chem; 2013 Jun; 288(25):18121-33. PubMed ID: 23649631
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
10. Regulator of G-protein signaling 4: A novel tumor suppressor with prognostic significance in non-small cell lung cancer.
Cheng C; Yue W; Li L; Li S; Gao C; Si L; Tian H
Biochem Biophys Res Commun; 2016 Jan; 469(3):384-91. PubMed ID: 26640232
[TBL] [Abstract][Full Text] [Related]
11. KISS1R induces invasiveness of estrogen receptor-negative human mammary epithelial and breast cancer cells.
Cvetkovic D; Dragan M; Leith SJ; Mir ZM; Leong HS; Pampillo M; Lewis JD; Babwah AV; Bhattacharya M
Endocrinology; 2013 Jun; 154(6):1999-2014. PubMed ID: 23525242
[TBL] [Abstract][Full Text] [Related]
12. GPR78 promotes lung cancer cell migration and metastasis by activation of Gαq-Rho GTPase pathway.
Dong DD; Zhou H; Li G
BMB Rep; 2016 Nov; 49(11):623-628. PubMed ID: 27697106
[TBL] [Abstract][Full Text] [Related]
13. Characterization and comparison of RGS2 and RGS4 as GTPase-activating proteins for m2 muscarinic receptor-stimulated G(i).
Cladman W; Chidiac P
Mol Pharmacol; 2002 Sep; 62(3):654-9. PubMed ID: 12181442
[TBL] [Abstract][Full Text] [Related]
14. N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells.
Bodenstein J; Sunahara RK; Neubig RR
Mol Pharmacol; 2007 Apr; 71(4):1040-50. PubMed ID: 17220356
[TBL] [Abstract][Full Text] [Related]
15. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.
Appaiah H; Bhat-Nakshatri P; Mehta R; Thorat M; Badve S; Nakshatri H
Cancer Biol Ther; 2010 Sep; 10(6):600-14. PubMed ID: 20603605
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance.
Medina-Ramirez CM; Goswami S; Smirnova T; Bamira D; Benson B; Ferrick N; Segall J; Pollard JW; Kitsis RN
Cancer Res; 2011 Dec; 71(24):7705-15. PubMed ID: 22037876
[TBL] [Abstract][Full Text] [Related]
17. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.
Baugher PJ; Krishnamoorthy L; Price JE; Dharmawardhane SF
Breast Cancer Res; 2005; 7(6):R965-74. PubMed ID: 16280046
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
19. Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion.
Xie Y; Abel PW; Kirui JK; Deng C; Sharma P; Wolff DW; Toews ML; Tu Y
Biochem Pharmacol; 2013 May; 85(10):1454-62. PubMed ID: 23500535
[TBL] [Abstract][Full Text] [Related]
20. Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells.
Wang Q; Liu-Chen LY; Traynor JR
J Biol Chem; 2009 Jul; 284(27):18357-67. PubMed ID: 19416973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
